Cerovations

Executive Summary

Cerovations is a Minnesota-based medical device company developing the OsmoFlo™ Bimodal EVD System, a novel device for treating cerebral edema and reducing intracranial pressure in severe traumatic brain injury (TBI) patients. Founded in 2017, the company is currently in the pre-clinical stage and has secured an NIH grant to support its development. Cerebral edema is a life-threatening condition with limited treatment options, and the OsmoFlo system aims to provide a more effective and precise therapeutic modality than current standard-of-care approaches. The device's bimodal mechanism of action could offer significant clinical benefits, potentially improving outcomes for TBI patients and reducing healthcare burdens. Cerovations is now planning first-in-human studies, marking a critical transition from preclinical development to clinical validation. While still early-stage, the company's focus on a high-need area and NIH funding support suggest a viable path forward. Given the early stage of development, Cerovations carries significant technological and regulatory risk. However, the large unmet medical need in TBI neurocritical care and the potential for a differentiated device provide upside. Key upcoming milestones include the initiation of first-in-human trials and further validation of the device's safety and efficacy. The company's ability to execute on clinical development and secure additional funding will be critical to its success. Overall, Cerovations represents a high-risk, high-reward opportunity in the medical device space, with a notable catalyst pipeline in the next 12-24 months.

Upcoming Catalysts (preview)

• Q3 2026Initiation of First-in-Human Study for OsmoFlo Bimodal EVD System60% success
• Q4 2026Completion of Preclinical / GLP Studies Required for IND/IDE70% success
• Q1 2027Securing Additional Funding (e.g., Series A or SBIR Phase II)50% success